Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
$34.49
$34.46
$10.09
$37.00
$2.26B1.761.71 million shsN/A
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
$18.17
$18.16
$8.00
$21.70
$1.85B1.45361,806 shsN/A
Arvinas, Inc. stock logo
ARVN
Arvinas
$7.89
-0.1%
$7.35
$5.90
$34.11
$576.63M2.171.46 million shs826,658 shs
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
$9.77
$0.49
$2.60
$2.35B1.5539,610 shs3.45 million shs
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$1.17
+1.8%
$0.98
$0.69
$3.94
$227.93M0.74.84 million shs2.32 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
0.00%0.00%0.00%0.00%0.00%
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
0.00%0.00%0.00%0.00%0.00%
Arvinas, Inc. stock logo
ARVN
Arvinas
+3.54%+1.28%+7.78%+14.49%-68.21%
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
0.00%0.00%0.00%0.00%0.00%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
+15.00%+13.86%+25.19%-10.85%-50.85%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Arvinas, Inc. stock logo
ARVN
Arvinas
3.1124 of 5 stars
4.32.00.00.00.02.51.3
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
N/AN/AN/AN/AN/AN/AN/AN/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
4.1413 of 5 stars
3.43.00.03.92.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
0.00
N/AN/AN/A
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
0.00
N/AN/AN/A
Arvinas, Inc. stock logo
ARVN
Arvinas
2.55
Moderate Buy$20.29157.12% Upside
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
0.00
N/AN/AN/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
2.80
Moderate Buy$7.00497.78% Upside

Current Analyst Ratings Breakdown

Latest ESPR, BLUSF, ARVN, AKCA, and AIMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/2/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$24.00
6/2/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$10.00 ➝ $9.00
6/1/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/15/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$74.00 ➝ $21.00
5/9/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.00
5/7/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $4.00
5/5/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.50
5/5/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$20.00 ➝ $10.00
5/5/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$21.00 ➝ $11.00
5/2/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$16.00
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
N/AN/AN/AN/A$1.66 per shareN/A
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
$488.54M3.78$0.51 per share35.54$5.78 per share3.14
Arvinas, Inc. stock logo
ARVN
Arvinas
$263.40M2.19N/AN/A$8.17 per share0.97
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
$30K0.00N/AN/A$0.25 per share0.00
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$332.31M0.70$0.02 per share47.86($1.97) per share-0.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
-$248.50M-$3.97N/AN/AN/AN/A-164.99%-89.50%N/A
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/A
Arvinas, Inc. stock logo
ARVN
Arvinas
-$198.90M-$0.66N/AN/AN/A-10.92%-7.74%-4.11%7/29/2025 (Estimated)
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$51.74M-$0.80N/AN/AN/A-59.03%-0.91%-29.47%8/11/2025 (Estimated)

Latest ESPR, BLUSF, ARVN, AKCA, and AIMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q2 2025
Arvinas, Inc. stock logo
ARVN
Arvinas
-$0.87N/AN/AN/A$34.42 millionN/A
5/6/2025Q1 2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$0.18-$0.21-$0.03-$0.21$54.97 million$65.00 million
5/1/2025Q1 2025
Arvinas, Inc. stock logo
ARVN
Arvinas
-$0.93$1.14+$2.07$1.14$41.87 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
N/AN/AN/AN/AN/A
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
N/AN/AN/AN/AN/A
Arvinas, Inc. stock logo
ARVN
Arvinas
N/AN/AN/AN/AN/A
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
N/AN/AN/AN/AN/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
0.73
7.53
7.40
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
N/A
12.17
11.78
Arvinas, Inc. stock logo
ARVN
Arvinas
N/A
4.58
4.58
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
N/A
13.87
13.87
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/A
1.18
0.81

Institutional Ownership

CompanyInstitutional Ownership
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
74.47%
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
19.27%
Arvinas, Inc. stock logo
ARVN
Arvinas
95.19%
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
N/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
47.39%

Insider Ownership

CompanyInsider Ownership
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
13.75%
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
1.50%
Arvinas, Inc. stock logo
ARVN
Arvinas
4.73%
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
24.17%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
1.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
22865.45 millionN/AOptionable
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
248101.60 millionN/AOptionable
Arvinas, Inc. stock logo
ARVN
Arvinas
42072.99 million69.54 millionOptionable
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
10159.12 millionN/ANot Optionable
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
200198.20 million194.83 millionOptionable

Recent News About These Companies

Esperion Appoints Craig Thompson to Board of Directors

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aimmune Therapeutics stock logo

Aimmune Therapeutics NASDAQ:AIMT

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Akcea Therapeutics stock logo

Akcea Therapeutics NASDAQ:AKCA

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.

Arvinas stock logo

Arvinas NASDAQ:ARVN

$7.89 -0.01 (-0.11%)
Closing price 02:37 PM Eastern
Extended Trading
$7.96 +0.07 (+0.87%)
As of 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

BELLUS Health stock logo

BELLUS Health OTCMKTS:BLUSF

BELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Esperion Therapeutics stock logo

Esperion Therapeutics NASDAQ:ESPR

$1.17 +0.02 (+1.83%)
Closing price 03:42 PM Eastern
Extended Trading
$1.16 -0.01 (-0.51%)
As of 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.